ProPublica flags FDA peptide reversal
What happened
A ProPublica investigation says the FDA reversed a 2023 decision that had placed 19 peptides on an 'unsafe' list, raising questions about whether oversight is loosening despite limited new safety data. If compounded peptide availability expands without stronger quality controls, distinguishing product‑specific signals from off‑label or variable‑quality compounding will become harder for pharmacovigilance teams. (propublica.org)
Why it matters
On Feb. 27, 2026, Health and Human Services Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience that he intends to reverse a 2023 decision by the Food and Drug Administration that had placed 19 injectable peptides on a list the agency deemed too unsafe for compounding by pharmacies. (podcasts.happyscribe.com) (propublica.org) Kennedy said roughly 14 of the 19 peptides are expected to move back to a permitted status for licensed compounding pharmacies, which would restore legal access to those formulations under a physician’s prescription, but reporters and industry trackers note the agency has not yet published a formal, updated bulks list. (peptibase.dev) (propublica.org) Under the FDA’s current system a “Category 1” bulk substance is a material the agency concludes can be used in compounding with appropriate controls, while “Category 2” denotes a bulk substance that the agency has identified as presenting significant safety risks and therefore is not eligible for routine compounding; the FDA published its Category 2 rationale and the listing mechanism in its bulks guidance. (fda.gov) (hhs.gov) The agency’s 2023 rationale for placing several peptides in Category 2 cited specific problems including the risk of immune reactions to injected peptide chains (“immunogenicity”), difficulties characterizing peptide impurities and the active pharmaceutical ingredient material, and “no or only limited” human safety data for certain routes of administration — for example, the FDA added BPC‑157 to Category 2 on Sept. 29, 2023 for those reasons. (fda.gov) (propublica.org) Compounded products are not approved drug products and are regulated under two pathways with different oversight: Section 503A pharmacies compound patient‑specific prescriptions and are overseen primarily by state pharmacy boards (and are generally not inspected by the federal agency), while Section 503B “outsourcing facilities” may register with and be inspected by the federal agency and must follow current good manufacturing practice standards; outsourcing facilities are required to submit adverse event reports to the agency under final guidance. (fda.gov) (ispe.org) (fda.gov) From a safety‑surveillance standpoint the federal agency’s Compounding Incidents Program uses reports to distinguish whether adverse events trace to a single facility’s process, to the active ingredient used across many facilities, or to other causes, and the return of widely used peptides to legal compounding will increase the number of facilities and formulations using the same APIs — a change that makes it harder to parse whether a safety signal arises from a specific manufacturer, an impure API batch, or off‑label use. (fda.gov 1) (fda.gov 2) Former senior agency officials quoted in the investigation say the 2023 listings were supported by documented safety concerns and warn that a reversal framed as “no safety signal” risks giving a broad imprimatur to unapproved products that have not completed standard clinical safety and effectiveness testing. (propublica.org)
Key numbers
- A ProPublica investigation says the FDA reversed a 2023 decision that had placed 19 peptides on an 'unsafe' list, raising questions about whether oversight is loosening despite limited new safety data.
- 27, 2026, Health and Human Services Secretary Robert F.
- said on The Joe Rogan Experience that he intends to reverse a 2023 decision by the Food and Drug Administration that had placed 19 injectable peptides on a list the agency deemed too unsafe for compounding by pharmacies.
What happens next
- If compounded peptide availability expands without stronger quality controls, distinguishing product‑specific signals from off‑label or variable‑quality compounding will become harder for pharmacovigilance teams.
Quick answers
What happened in ProPublica flags FDA peptide reversal?
A ProPublica investigation says the FDA reversed a 2023 decision that had placed 19 peptides on an 'unsafe' list, raising questions about whether oversight is loosening despite limited new safety data. If compounded peptide availability expands without stronger quality controls, distinguishing product‑specific signals from off‑label or variable‑quality compounding will become harder for pharmacovigilance teams. (propublica.org)
Why does ProPublica flags FDA peptide reversal matter?
On Feb. 27, 2026, Health and Human Services Secretary Robert F. Kennedy Jr. said on The Joe Rogan Experience that he intends to reverse a 2023 decision by the Food and Drug Administration that had placed 19 injectable peptides on a list the agency deemed too unsafe for compounding by pharmacies. (podcasts.happyscribe.com) (propublica.org) Kennedy said roughly 14 of the 19 peptides are expected to move back to a permitted status for licensed compounding pharmacies, which would restore legal access to those formulations under a physician’s prescription, but reporters and industry trackers note the agency has not yet published a formal, updated bulks list. (peptibase.dev) (propublica.org) Under the FDA’s current system a “Category 1” bulk substance is a material the agency concludes can be used in compounding with appropriate controls, while “Category 2” denotes a bulk substance that the agency has identified as presenting significant safety risks and therefore is not eligible for routine compounding; the FDA published its Category 2 rationale and the listing mechanism in its bulks guidance. (fda.gov) (hhs.gov) The agency’s 2023 rationale for placing several peptides in Category 2 cited specific problems including the risk of immune reactions to injected peptide chains (“immunogenicity”), difficulties characterizing peptide impurities and the active pharmaceutical ingredient material, and “no or only limited” human safety data for certain routes of administration — for example, the FDA added BPC‑157 to Category 2 on Sept. 29, 2023 for those reasons. (fda.gov) (propublica.org) Compounded products are not approved drug products and are regulated under two pathways with different oversight: Section 503A pharmacies compound patient‑specific prescriptions and are overseen primarily by state pharmacy boards (and are generally not inspected by the federal agency), while Section 503B “outsourcing facilities” may register with and be inspected by the federal agency and must follow current good manufacturing practice standards; outsourcing facilities are required to submit adverse event reports to the agency under final guidance. (fda.gov) (ispe.org) (fda.gov) From a safety‑surveillance standpoint the federal agency’s Compounding Incidents Program uses reports to distinguish whether adverse events trace to a single facility’s process, to the active ingredient used across many facilities, or to other causes, and the return of widely used peptides to legal compounding will increase the number of facilities and formulations using the same APIs — a change that makes it harder to parse whether a safety signal arises from a specific manufacturer, an impure API batch, or off‑label use. (fda.gov 1) (fda.gov 2) Former senior agency officials quoted in the investigation say the 2023 listings were supported by documented safety concerns and warn that a reversal framed as “no safety signal” risks giving a broad imprimatur to unapproved products that have not completed standard clinical safety and effectiveness testing. (propublica.org)
